BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 21, 2019--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a
biopharmaceutical company focused on the formulation, development, and
commercialization of innovative therapies for diseases and conditions of the
eye, today announced that it will
host a Research & Development Day to provide updates on the commercial
plans for DEXTENZA and a deeper dive into the hydrogel platform and the
Company's pipeline. The event will include presentations by members
of Ocular Therapeutix's senior management team and will include Key Opinion
Leaders Tal Raviv, MD, FACS, Founder and Medical Director, Eye Center of New
York; Kuldev Singh, MD, Professor of Ophthalmology and Director of the Glaucoma
Service, Stanford University Medical Center; and Elias Reichel, MD, Director,
Vitreoretinal Diseases and Surgery Service, Vice Chair, Department of
Ophthalmology, Tufts University School of Medicine.
The presentations will begin at 7:30 a.m. Eastern Time on Thursday,
March 28, 2019 in New York, New York.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company's website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation, development,
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary bioresorbable hydrogel-based
formulation technology. Ocular Therapeutix's first commercial drug
product, DEXTENZA®, is FDA-approved for the treatment of
ocular pain following ophthalmic surgery. OTX-TP (intracanalicular
travoprost insert) is an intracanalicular insert in Phase 3 clinical
development for the reduction of intraocular pressure in patients with
primary open-angle glaucoma and ocular hypertension. The Company's
earlier stage assets include OTX-TIC, an extended-delivery intracameral
travoprost implant for the reduction of intraocular pressure in patients
with glaucoma and ocular hypertension, as well as sustained release
intravitreal implants for the treatment of retinal diseases. These
intravitreal implants include OTX-TKI, containing a tyrosine kinase
inhibitor (TKI), and, in collaboration with Regeneron, OTX-IVT, an
extended-delivery protein-based anti-vascular endothelial growth factor
(VEGF) trap. Ocular Therapeutix's first product, ReSure®
Sealant, is FDA-approved to seal corneal incisions following cataract
View source version on businesswire.com: https://www.businesswire.com/news/home/20190321005385/en/
Source: Ocular Therapeutix, Inc.
Chief Financial Officer
Chris Brinzey, 339-970-2843
Senior Vice President, Commercial